Glycogen synthase kinase (GSK)-3β is a multifunctional protein that has been implicated in the pathological characteristics of Alzheimer’s disease (AD), including the heightened levels of neurofibrillary tangles, amyloid-beta (Aβ), and neurodegeneration. We have previously shown that an antisense oligonucleotide directed at the Tyr 216 site on GSK-3β (GAO) when injected centrally can decrease GSK-3β levels, improve learning and memory, and decrease oxidative stress. In addition, we showed that GAO can cross the blood-brain barrier. Herein the impact of peripherally administered GAO in both the non-transgenic SAMP8 and transgenic Tg2576 (APPswe) models of AD were examined respective to learning and memory. Brain tissues were then evaluated for expression changes in the phosphorylated-Tyr 216 residue, which leads to GSK-3β activation, and the phosphorylated-Ser9 residue, which reduces GSK-3β activity. SAMP8 GAO-treated mice showed improved acquisition and retention using aversive T-maze, and improved declarative memory as measured by the novel object recognition (NOR) test. Expression of the phosphorylated-Tyr 216 was decreased and the phosphorylated-Ser9 was increased in GAO-treated SAMP8 mice. Tg2576 GAO-treated mice improved acquisition and retention in both the T-maze and NOR tests, with an increased phosphorylated-Ser9 GSK-3β expression. Results demonstrate that peripheral administration of GAO improves learning and memory, corresponding with alterations in GSK-3β phosphorylation state. This study supports peripherally administered GAO as a viable means to mediate GSK-3β activity within the brain and a possible treatment for AD.
Kaidanovich-BeilinO, WoodgettJR (2011) GSK-3: Functional insights from cell biology and animal models. Front Mol Neurosci4, 40.
2.
HooperC, KillickR, LovestoneS (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem104, 1433–1439.
3.
MartinezA, GilC, PerezDI (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment. Int J Alzheimers Dis2011, 1–7.
4.
XiYL, LiHX, ChenC, LiuYQ, LvHM, DongSQ, LuoEF, GuMB, LiuH (2016) Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle, through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway. Chin J Nat Med14, 48–55.
5.
LiB, ThrasherJB, TerranovaP (2015) Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. Urol Oncol33, 456–463.
6.
LazzaraCA, KimYH (2015) Potential application of lithium in Parkinson’s and other neurodegenerative diseases. Front Neurosci9, 403.
7.
ForlenzaOV, De-PaulaVJ, DinizBS (2014) Neuroprotective effects of lithium: Implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders. ACS Chem Neurosci5, 443–450.
8.
MedinaM, AvilaJ (2013) Understanding the relationship between GSK-3 and Alzheimer’s disease: A focus on how GSK-3 can modulate synaptic plasticity processes. Expert Rev Neurother13, 495–503.
9.
Llorens-MartinM, JuradoJ, HernandezF, AvilaJ (2014) GSK-3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci7, 46.
10.
QianW, ShiJ, YinX, IqbalK, Grundke-IqbalI, GongCX, LiuF (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis19, 1221–1229.
11.
HangerDP, NobleW (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis2011, 352805.
12.
YagiH, KatohS, AkiguchiI, TakedaT (1988) Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Neurosci Biobehav Rev474, 86–93.
13.
FloodJF, MorleyJE (1998) Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev22, 1–20.
14.
MorleyJE, KumarVB, BernardoAI, FarrSA, UezuK, TumosaN, FloodJF (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides21, 1761–1767.
15.
PallasM, CaminsA, SmithMA, PerryG, LeeHG, CasadesusG (2008) From aging to Alzheimer’s disease: Unveiling “the switch” with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis15, 615–624.
16.
ButterfieldDA, StadtmanER (1997) Protein oxidation processes in aging brain. Adv Cell Aging Gerontol2, 161–191.
17.
PoonHF, CastegnaA, FarrSA, ThongbookerdV, LynnBC, BanksWA, MorleyJE, KleinJB, ButterfieldDA (2004) Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mouse brain. Neuroscience126, 915–926.
18.
EricksonMA, NiehoffML, FarrSA, MorleyJE, DillmanLA, LynchKM, BanksWA (2012) Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses ABPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis28, 951–960.
19.
FarrSA, RipleyJL, SultanaR, ZhangZ, NiehoffML, PlattTL, MurphyMP, MorleyJE, KumarV, ButterfieldDA (2014) Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med67, 387–395.
20.
TajesM, Yeste-VelascoM, ZhuX, ChouSP, SmithMA, PallasM, CaminsA, CasadesusG (2009) Activation of Akt by lithium: Pro-survival pathways in aging. Mech Ageing Dev130, 253–261.
21.
HsaioK, ChapmanP, NilsenS, ErkmanC, HarigayaY, YangF, ColeG (1996) Correlative memory deficits, AB elevation, and amyloid plaques in transgenic mice. Science274, 99–102.
22.
DobarroM, GerenuG, RamierzMJ (2013) Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer’s transgenic mice. Int J Neuropsychopharmacol16, 2245–2257.
23.
Castillo-CarranzaDL, Guerrero-MunozMJ, SenguptaU, HernandezC, BarrettAD, DineleyK, KayedR (2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer’s disease mouse model. J Neurosci35, 4857–4868.
24.
HammondRS, TullLE, StackmanRW (2004) On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem82, 26–34.
25.
LovestoneS, ReynoldsCH, LatimerD, DavisDR, AndertonBH, GalloJM, HangerD, MulotS, MarquardtB, StabelS, WoodgettJR, MillerCCJ (1994) Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol4, 1077–1086.
26.
YamaguchiH, IshiguroK, UchidaT, TakashimaA, LemereCA, ImahoriK (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol92, 232–241.
27.
HongM, ChenDC, KleinPS, LeeVM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem272, 25326–25332.
28.
EngelT, Goni-OliverP, LucasJJ, AvilaF, HernandezF (2006) Chronic lithium administration of FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem99, 1445–1455.
29.
LucasJJ, HernandezF, Gomez-RamosP, MoranMA, HenR, AvilaJ (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J20, 27–39.
30.
PeiJJ, TanakaT, TungYC, BraakE, IqbalK, Grundke-IqbalI (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol56, 70–78.
31.
LeroyK, YilmazZ, BrionJP (2007) Increased level of active GSK-3beta in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Applied Neurobiol33, 43–55.
32.
FuZQ, YangY, SongJ, JiangQ, LinZC, WangQ, ZhuLQ, WangJZ, TianQ (2010) LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro. J Alzheimers Dis21, 1107–1117.
PeiJJ, BraakE, BraakH, Grundke-IqbalI, IqbalK, WinbladB, CowburnRF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol58, 1010–1019.
36.
BlalockEM, GeddesJW, ChenKC, PorterNM, MarkesberyWR, LandfieldPW (2004) Incipient Alzheimer’s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A101, 2173–2178.
37.
KannoT, TsuchiyaA, NishizakiT (2014) Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav Brain Res274, 302–306.
38.
SannaPP, CammalleriM, BertonF, SimpsonC, LutjensR, BloomFE, FrancesconiW (2002) Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J Neurosci22, 3359–3365.
39.
LiuSJ, ZhangAH, LiHL, WangQ, DengHM, NetzerWJ, XuH, WangJZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem87, 1333–1344.
40.
ArmbrechtHJ, SiddiquiAM, GreenM, FarrSA, KumarVB, BanksWA, PatrickP, ShahGN, MorleyJE (2014) SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways. Neurobiol Aging35, 159–168.
TammI (2008) AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for potential tretment of cancer. Curr Opin Investig Drugs9, 638–646.
43.
EversMM, ToonenLJ, van Roon-MomWM (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev87, 90–103.
44.
LippiG, HarenbergJ, MattiuzziC, FavaloroEJ (2015) Next generation antithrombotic therapy: Focus on antisense therapy against coagulation factor XI. Semin Thromb Hemost41, 255–262.
